Activin RIA/ALK‑2 was detected in immersion fixed paraffin-embedded sections of human astrocytoma using 15 µg/mL Goat Anti-Human Activin RIA/ALK‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF637) ...read more
PC‑3 human prostate cancer cell line was stained with Goat Anti-Human Activin RIA/ALK‑2 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF637, filled histogram) or control antibody (Catalog # AB-108-C, ...read more
Activin RIA/ALK‑2 was detected in immersion fixed paraffin-embedded sections of human placenta using Goat Anti-Human Activin RIA/ALK‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF637) at 15 µg/mL ...read more
Activin RIA/ALK-2/Activin Receptor Type 1 Antibody Summary
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Activin RIA/ALK-2 Asp23-Glu123 Accession # Q04771
Detects human Activin RIA/ALK‑2 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) Activin RIB, rhActivin RIIA, and rhActivin RIIB is observed.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Activin RIA/ALK-2/Activin Receptor Type 1 Antibody
activin A receptor, type I
Activin isoforms and other members of the TGF-beta superfamily exert their biological effects by binding to heteromeric complexes of a type I and a type II serine‑threonine kinase receptor, both of which are essential for signal transduction. To date, seven type I and five type II receptors, including the two type I and the two type II activin receptors, designated ActR-I(A), ActR-IB, ActR-II(A), and ActR-IIB, have been cloned from mammals. Through alternative mRNA splicing, multiple ActR-IIB isoforms can also be generated, adding to the complexity of the activin receptor system. Different activin isoforms bind with different high-affinities to the various type II isoforms. Type I activin receptors do not bind directly to activin but will associate with the type II receptor-activin complex and initiate signal transduction. Besides the activin isoforms, ActR-II will also bind inhibin, BMP-2 and BMP-7 with lower affinities. ActR-I can also bind and form signaling complexes with the BMP-2/7-bound BMPR-II. Activin type I receptors are highly conserved. Human, mouse and bovine type IA activin receptors share greater than 98% amino acid sequence homology. Recombinant soluble activin type I receptor does not bind activin.
Attisano, L. et al. (1996) Mol. and Cell. Biol. 16:1066.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Activin RIA/ALK-2/Activin Receptor Type 1 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.